Edgewise Therapeutics Inc., a leading biopharmaceutical company focused on muscle diseases, announced new compensation terms as part of their 2024 Inducement Equity Incentive Plan. On July 31, 2025, the company granted inducement stock options to purchase 84,250 shares and inducement restricted stock units (RSUs) covering 5,000 shares to three new non-executive employees. The stock options have an exercise price of $14.26 per share, the closing price on the grant date. They will vest with 25% of the shares on the first anniversary of the employees' start date, and 1/48th of the shares monthly thereafter. The RSU awards will vest in equal annual installments over four years, starting on July 31, 2025, contingent on the employees' continued service. These grants are aligned with Nasdaq Listing Rule 5635(c)(4).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。